spacer
home > epc > autumn 2017 > compliance and modernisation
PUBLICATIONS
European Pharmaceutical Contractor

Compliance and Modernisation

The new ICH Good Clinical Practice (GCP) E6 Addendum Revision 2 (E6 R2) is the biggest amendment of the international guideline for over 20 years. The update was finalised in November 2016 and became effective in the EU on 14 June 2017, meaning organisations running clinical trials in this region should now be compliant with the new requirements.

However, in January 2017 – just two months after the new guideline was finalised – many were surprised when ICH announced that an even greater change is planned. The extra revision is being added to keep pace with the scale and complexity of clinical trials and to ensure appropriate use of technology.

Further Modernisation

ICH is proposing further updates to E6 R2 in what they are calling a ‘renovation’ – the scope of these further suggested changes will include clinical trial design, planning, management and conduct of clinical trials (1).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Laura Brown is Managing Director of a leading international training and quality assurance consultancy specialising in the pharmaceutical industry. She delivers a broad range of technical and management courses and consultancy for pharma, covering project management, ICH GCP R2, CAPA and clinical trial regulations. Laura is also Course Director, MSc Clinical Research, School of Pharmacy, Cardiff University, UK.
spacer
Dr Laura Brown
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Bioclinica Announces AB Cube Has Joined eHealth App xChange


More info >>

White Papers

Generating Scientific Insights by Deep Collaboration - Bridging the Big Data Divide Between Clinical and Research

BioFortis

Translational research, biomarker discovery, clinical studies and even biobanking have become increasingly data intensive.  However, generating scientific insights from such disparate “big” data sources across multiple domains is a challenge for both researchers and the informaticians that support them. Download our Deep Collaboration Whitepaper and and learn how to bridge the clinical and research divide to better explore your biomarker based trials.
More info >>

 
Industry Events

6th Annual Cancer Vaccines Conference

27-28 September 2017, Copthorne Tara Hotel, London UK

Cancer Vaccines 2017: Overcoming hurdles to cancer immune response: Cell therapies, vaccine development and combination therapies. SMi Group is thrilled to present the 6th annual Cancer Vaccines conference, taking place on 27th & 28th September 2017 in Central London, UK. Overcoming hurdles to cancer immune response: Cell therapies, vaccine development and combination therapies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement